Monogram Orthopaedics Awaits FDA Clearance for mBôs TKA System

Monogram Orthopaedics Inc ( (MGRM) ) has shared an update.

On February 25, 2025, Monogram Technologies Inc. announced the completion of supplemental testing and submission of a formal response to the FDA’s Additional Information Request for its mBôs TKA System. The company anticipates a favorable clearance decision, which would allow commercialization in the U.S. Monogram also held an Investigator Meeting in India as part of a collaboration with Shalby Limited and Reliance Life Sciences to prepare for a clinical trial of the mBôs TKA System. The company has made significant advancements in its robotic system, enhancing cutting speeds and maintaining accuracy, positioning it as a competitive solution in the orthopedic robotics market.

More about Monogram Orthopaedics Inc

Monogram Technologies Inc. is an AI-driven robotics company focused on improving human health, particularly in orthopedic surgery. The company aims to develop patient-optimized orthopedic implants at scale by integrating 3D printing, advanced machine vision, AI, and next-generation robotics. Monogram’s mBôs precision robotic surgical system is designed for high-precision insertion of FDA-cleared implants, with the goal of achieving well-balanced, better-fitting knee replacements.

YTD Price Performance: -5.46%

Average Trading Volume: 58,694

Technical Sentiment Consensus Rating: Strong Buy

Learn more about MGRM stock on TipRanks’ Stock Analysis page.